Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Completed 2Withdrawn 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other solid neoplasm 3

Conditions

Solid Tumor 2Advanced Solid Tumors 1

Interventions

Cisplatin 145pembrolizumab 129Carboplatin 125Injections 108Pemetrexed 97Paclitaxel 97Gemcitabine 85Irinotecan 75Nivolumab 71Cyclophosphamide 71Docetaxel 68Bevacizumab 57Oxaliplatin 49Fluorouracil 48atezolizumab 46Capecitabine 46Etoposide 42Leucovorin 41tislelizumab 40toripalimab 36fludarabine 32Ipilimumab 30Drug Therapy 30Topotecan 29durvalumab 28Vincristine 27Early Intervention, Educational 27Radiotherapy 26Interviews as Topic 26Specimen Handling 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × navoximod × Other solid neoplasm × Clear all
NCT05469490 2022-09-30

Safety of Navoximod and NLG802 With Stereotactic Body Radiotherapy (SBRT) Treatment of Advanced Solid Tumors

University of Pittsburgh

Phase 1 Withdrawn
Other solid neoplasm

Advanced Solid Tumors

NCT02471846 2019-10-22

A Study of GDC-0919 and Atezolizumab Combination Treatment in Participants With Locally Advanced or Metastatic Solid Tumors

Genentech, Inc.

Phase 1 Completed
158 enrolled
Other solid neoplasm

Solid Tumor

NCT02048709 2017-02-06

Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Advanced Solid Tumors

Genentech, Inc.

Phase 1 Completed
22 enrolled
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡